This is similar to findings in an earlier phase I/II trial in advanced pancreatic cancer, where only stromal SPARC expression appeared to be an effective marker of increased activity of nab-paclitaxel [45]. The gene discussed is SPARC; the disease is familial pancreatic carcinoma.